The established grading criteria for IDH-mutant astrocytomas are histological criteria including brisk mitotic activity (CNS WHO grade 3), as well as necrosis and/or microvascular proliferation (CNS WHO grade 4). This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).